Perceptive Advisors LLC Purchases Shares of 12,050,000 Palisade Bio, Inc. $PALI

Perceptive Advisors LLC purchased a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 4th quarter, Holdings Channel.com reports. The firm purchased 12,050,000 shares of the company’s stock, valued at approximately $28,318,000. Perceptive Advisors LLC owned approximately 0.08% of Palisade Bio as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the company. Commodore Capital LP purchased a new position in Palisade Bio during the 4th quarter valued at approximately $26,896,000. Janus Henderson Group PLC purchased a new position in Palisade Bio during the 4th quarter valued at approximately $24,822,000. RA Capital Management L.P. purchased a new position in Palisade Bio during the 4th quarter valued at approximately $16,742,000. Eversept Partners LP purchased a new position in Palisade Bio during the 4th quarter valued at approximately $12,670,000. Finally, Franklin Resources Inc. purchased a new position in Palisade Bio during the 4th quarter valued at approximately $11,968,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Analysts Set New Price Targets

PALI has been the subject of several research analyst reports. Stifel Nicolaus initiated coverage on Palisade Bio in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target for the company. Weiss Ratings cut Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wolfe Research initiated coverage on Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Finally, HC Wainwright initiated coverage on Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Palisade Bio presently has an average rating of “Moderate Buy” and a consensus target price of $10.20.

Palisade Bio Price Performance

NASDAQ:PALI opened at $1.76 on Thursday. The firm has a market capitalization of $305.50 million, a price-to-earnings ratio of -1.74 and a beta of 1.52. Palisade Bio, Inc. has a 1 year low of $0.53 and a 1 year high of $2.86. The business has a 50 day simple moving average of $1.97 and a 200-day simple moving average of $1.90.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, analysts expect that Palisade Bio, Inc. will post -0.21 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.